Compare ECO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | MESO |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Greece | Australia |
| Employees | N/A | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2023 | N/A |
| Metric | ECO | MESO |
|---|---|---|
| Price | $55.45 | $16.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $42.00 | N/A |
| AVG Volume (30 Days) | ★ 359.3K | 187.2K |
| Earning Date | 05-13-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.07 | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.27 | $9.88 |
| 52 Week High | $57.29 | $21.50 |
| Indicator | ECO | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 64.52 | 55.57 |
| Support Level | $48.57 | $15.62 |
| Resistance Level | $57.29 | $16.37 |
| Average True Range (ATR) | 2.07 | 0.38 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 83.98 | 47.49 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.